Biopharma's Paradox: Innovation Stalled by Commercial Silos

EVANSTON, Ill. – January 29, 2026 – The biopharmaceutical industry is in the midst of one of its most productive eras, delivering an unprecedented wave of new medicines. Yet, a landmark new report reveals a critical paradox: the operational systems designed to bring these treatments to patients are failing to keep pace, creating a bottleneck that stalls innovation and hinders access.

Beghou, a life sciences consulting firm with a 30-year history in the sector, today released its inaugural Biopharma Commercialization Research Report. The findings, based on a survey of 140 U.S.-based industry leaders, paint a stark picture of an industry struggling with internal friction. Despite heavy investment in data, technology, and talent, companies are hampered by a fundamental lack of coordination, resulting in what the report calls “yawning gaps between what teams know to do and what they can deliver together.”

“Today’s biopharma launches are less like a marathon and more like a sprint, but our research shows many teams have yet to adjust how they operate,” stated Marc Iskowitz, Editorial Director at Beghou. The consequences are significant: misaligned timing, siloed execution, and a failure to translate good strategies into great results for patients and providers.

The Coordination Crisis

The report identifies a core challenge that is more organizational than technological. While teams are focused on the right priorities—building data infrastructure, investing in AI, and planning across functions—they are often not doing so in concert. This disjointed approach is exacerbated by dynamic team structures and uncertain market conditions.

A striking 60% of respondents reported being on launch teams working together for the first time, and nearly half were not highly confident in their planning horizon. This lack of collective experience and foresight creates a fragile environment where even minor disruptions can derail a launch. The most-cited factor having a negative impact on commercialization success was not a lack of effort, but a failure of integration: late or incomplete data connections, siloed systems, and reliance on legacy platforms.

While cross-functional alignment and early planning were reported as the most positive factors impacting success, the data shows this is more of an ideal than a consistent reality. The report suggests that the industry's ability to deliver on its promise is being compromised by these persistent system-level gaps, preventing the full value of new medicines from being realized.

AI: A Brain for Strategy, Still Learning to Act

Nowhere is the gap between potential and practice more evident than in the adoption of artificial intelligence. The report highlights a major disparity in how AI is being leveraged. An overwhelming 80% of data and analytics leaders reported that AI's greatest impact is in generating strategic insights—clarifying which patients may benefit from a treatment and where to focus commercial efforts.

However, when it comes to execution, the numbers plummet. Only 30% of the same respondents considered AI impactful for direct customer engagement. This suggests that while biopharma has successfully built a powerful analytical “brain” to process vast amounts of data, it is still learning how to translate those insights into effective, real-world actions with healthcare professionals and patients.

This gap is reflected in investment priorities. Over the next 12 to 18 months, leaders plan to prioritize foundational elements, with 50% focusing on commercial data infrastructure and 47% on acquiring non-traditional or real-world data (RWD) sources. In contrast, investment in Generative and agentic AI for direct commercialization is a much lower priority at 20%. This indicates a strategic, “walk before you run” approach, where companies recognize the need to build a solid, integrated data foundation before they can effectively deploy advanced AI for execution. The report also notes that certain hyped technologies, such as AI for forecasting, were among the investments that most often fail to live up to expectations, reinforcing the need for pragmatic, well-integrated solutions over standalone novelties.

The High Cost of a Disjointed Tech Stack

The report confirms that investment in technology is accelerating, but simply acquiring more tools is not solving the problem. The core issue is a lack of harmony. When disparate systems cannot communicate or surface answers quickly, companies lose the agility needed to adapt to fast-changing market dynamics.

Data and analytics leaders who reported having aligned technology stacks also expressed higher confidence in their planning horizons, directly linking technological cohesion to strategic assurance. Conversely, a fragmented tech environment breeds uncertainty and undermines data credibility, as teams are often forced to operate from different sources of truth.

Although commercial operations leaders identified integrated commercial platforms (70%) and digital field enablement tools (63%) as justified expenditures, the underlying challenge remains one of orchestration. Without a unified system, even best-in-class tools can become part of the problem, adding another layer of complexity instead of simplifying operations. The findings underscore that future success will depend less on the number of technologies a company owns and more on its ability to make them work as a single, responsive system.

Orchestration: The New Mandate for Commercial Success

To close the gap between innovation and execution, the report advocates for a new operational mandate: orchestration. This framework calls for the deliberate and synchronized evolution of four key dimensions: strategy, teams, technology, and data. The research argues that these elements have evolved, but they have not evolved together.

• Strategy: Moving beyond broad patient-centric goals to a consistent, cross-functional interpretation that informs every patient interaction.
• Teams: Fostering earlier collaboration and clearer ownership to reduce friction and improve collective decision-making.
• Technology: Building an aligned tech stack that enables shared visibility and rapid response rather than a collection of siloed tools.
• Data: Establishing a single source of truth that improves data credibility and supports real-time adjustments across the organization.

According to Iskowitz, this coordinated approach is what will separate the leaders from the laggards in the coming years. “Over the next 18 months, the leaders won’t just be those who invest in the right capabilities,” he stated. “Those who coordinate what’s mission-critical are the ones who will set the new standard for commercialization excellence.”

The path forward for the biopharma industry is not about adding more activity, but about enabling better, more harmonious coordination across the entire commercial system. By orchestrating these critical elements, companies can finally ensure that their groundbreaking scientific achievements translate into meaningful and timely value for the patients they aim to serve.